Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases [0.03%]
洛拉替尼治疗ALK重排型NSCLC患者引起的需要神经外科手术的放射性脑病：两例报告
Viola W Zhu,Misako Nagasaka,Takafumi Kubota et al.
Viola W Zhu et al.
Central nervous system (CNS) metastasis carries a significant morbidity and mortality in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Next-generation ALK tyrosine kinase inhibitors (TKIs) are highly CNS-pe...
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer [0.03%]
当前关于石棉引起肺癌的表观遗传学改变的研究理解
Yuen Yee Cheng,Emma M Rath,Anthony Linton et al.
Yuen Yee Cheng et al.
Asbestos is a naturally occurring mineral consisting of extremely fine fibres that can become trapped in the lungs after inhalation. Occupational and environmental exposures to asbestos are linked to development of lung cancer and malignant...
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies [0.03%]
克唑替尼治疗后使用艾乐替尼患者的阳性非小细胞肺癌（NSCLC）的NP28673和NP28761二期研究中的反应持续时间
Shirish Gadgeel,Alice T Shaw,Fabrice Barlesi et al.
Shirish Gadgeel et al.
Introduction: Alectinib is a highly selective and potent ALK inhibitor, approved for the treatment of patients with metastatic ALK+ NSCLC based on results from the Phase II global NP28673 (NCT01801111) and North American ...
Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer [0.03%]
立体定向体部放射治疗用于早期非小细胞肺癌的效果：调强放疗与三维适形放疗比较
Michael Mix,Sean Tanny,Tamara Nsouli et al.
Michael Mix et al.
Introduction: The treatment techniques used for stereotactic body radiation therapy (SBRT) for early-stage lung cancer continue to evolve. In this study, clinical outcomes following SBRT were evaluated according to the us...
Chiara Baldovini,Giulio Rossi,Alessia Ciarrocchi
Chiara Baldovini
Pulmonary sarcomatoid carcinoma (PSC) is a heterogeneous category of primary lung cancer accounting from 0.3% to 3% of all primary lung malignancies. According to the most recent 2015 World Health Organization (WHO) classification, PSC incl...
Natthaya Triphuridet,Claudia Henschke
Natthaya Triphuridet
Lung cancer remains the leading cause of cancer incidence and mortality worldwide. Approximately 60% of the world's new cases of lung cancer and deaths from it are expected in Asia in 2018. Currently, lung cancer screening using low-dose co...
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations [0.03%]
携带二次CTNNB1 p.S45V和三次ALK p.I1171N突变的TKI耐药性重排肺腺癌
Madhu M Ouseph,Angela Taber,Humera Khurshid et al.
Madhu M Ouseph et al.
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is an important molecular subgroup of tumors that are typically sensitive to tyrosine kinase inhibitors (TKIs). Although a substantial portion of patients benefi...
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors [0.03%]
评估肿瘤体积(PTV)作为非小细胞肺癌(NSCLC)患者预测PD-1抑制剂疗效的预处理标志物的回顾性研究
Misako Nagasaka,Nadine Abdallah,Marcus Crosby et al.
Misako Nagasaka et al.
Introduction of hypothesis: Little information is available regarding the imaging characteristics that assist in differentiating responders from non-responders. We hypothesized that patients with higher pretreatment tumor...
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date [0.03%]
恩曲替尼及其在ROS1阳性NSCLC治疗中的潜力：迄今为止的证据
Francesco Facchinetti,Luc Friboulet
Francesco Facchinetti
ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lun...
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients [0.03%]
吸烟对印尼未经治疗的肺癌患者中K-RAS和EGFR突变频率和谱系的影响
Najmiatul Masykura,Jamal Zaini,Elisna Syahruddin et al.
Najmiatul Masykura et al.
Background: Indonesia has the highest cigarette consumption in the world. We explored the clinical impact of smoking on the prevalence of EGFR and K-RAS mutations and survival in this prospective study. Methods: 143 treatment naive lung can...